Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Dexrazoxane cost effective in preventing anthracycline cardiotoxicity

    • 4 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Dewilde S, et al. Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective. Cost Effectiveness and Resource Allocation : No. 18, 10 Feb 2020. Available from: URL: https://doi.org/10.1186/s12962-020-0205-4

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Dexrazoxane cost effective in preventing anthracycline cardiotoxicity. Reactions Weekly 1791, 8 (2020). https://doi.org/10.1007/s40278-020-74853-5

    Download citation